Innobiochips Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Financing Rounds
  • 5

Innobiochips General Information

Description

Developer of multiplex diagnostic technology intended for the healthcare sector. The company's technology uses a surface functionalization method that can be implemented on standard laboratory equipment, enabling clients to run up many tests using a single biological sample for accurate and quick results.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • Parc Eurasanté Lille Métropole
  • 70 Rue du Dr Yersin
  • 59120 Loos
  • France
+33 03
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • Parc Eurasanté Lille Métropole
  • 70 Rue du Dr Yersin
  • 59120 Loos
  • France
+33 03

Innobiochips Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Innobiochips Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Innobiochips‘s full profile, request access.

Request a free trial

Innobiochips Patents

Innobiochips Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3106900-B1 Method for capturing and identifying cell agglutinates for multiplex detection of anti-erythrocyte antibodies Active 04-Feb-2020
JP-2023515730-A Method for capturing and identifying cell aggregates to detect multiple anti-erythrocyte antibodies Pending 04-Feb-2020
EP-4100745-A1 Method for capturing and identifying cellular agglutinates for detecting multiplex anti-erythrocyte antibodies Pending 04-Feb-2020
US-20230062669-A1 Method for capturing and identifying cellular agglutinates for detecting multiplex anti-erythrocyte antibodies Pending 04-Feb-2020
FR-3106900-A1 Process for the capture and identification of cellular agglutinates for the detection of multiplexed anti-erythrocyte antibodies Active 04-Feb-2020 G01N33/80
To view Innobiochips’s complete patent history, request access »

Innobiochips Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Innobiochips Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Innobiochips‘s full profile, request access.

Request a free trial

Innobiochips FAQs

  • When was Innobiochips founded?

    Innobiochips was founded in 2008.

  • Where is Innobiochips headquartered?

    Innobiochips is headquartered in Loos, France.

  • What is the size of Innobiochips?

    Innobiochips has 15 total employees.

  • What industry is Innobiochips in?

    Innobiochips’s primary industry is Biotechnology.

  • Is Innobiochips a private or public company?

    Innobiochips is a Private company.

  • What is Innobiochips’s current revenue?

    The current revenue for Innobiochips is .

  • How much funding has Innobiochips raised over time?

    Innobiochips has raised $2.32M.

  • Who are Innobiochips’s investors?

    Nord France Amorçage, Autonomie & Solidarité, Inovam Brasil, Finovam Gestion, and Siparex Group have invested in Innobiochips.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »